Skip to main content

Prevalence of Cirrhosis Higher in Transgender Versus Cisgender Adults

Medically reviewed by Carmen Pope, BPharm. Last updated on July 29, 2024.

By Elana Gotkine HealthDay Reporter

MONDAY, July 29, 2024 -- Transgender adults have higher prevalence of cirrhosis, but they do not have increased incidence of liver-related outcomes or all-cause mortality, according to a study published online June 25 in the American Journal of Gastroenterology.

Hirsh Elhence, from the Keck School of Medicine at the University of Southern California in Los Angeles, and colleagues identified all transgender and cisgender adults to calculate the age-standardized prevalence of cirrhosis. Age-standardized incidence densities of liver-related outcomes (decompensation, transplantation, and hepatocellular carcinoma) and all-cause mortality were calculated among those with incident cirrhosis diagnoses. Using inverse probability treatment weighting to balance transgender and cisgender populations on demographic and clinical characteristics, five-year survival was examined.

Overall, 0.07 percent of the 64.6 million adults were transgender, and 0.09 percent of the 329,251 adults with cirrhosis were transgender. The researchers found that the prevalence of cirrhosis was higher for transgender versus cisgender adults (1,285 versus 561 per 100,000). Among those with cirrhosis, compared with cisgender adults, transgender adults had higher proportions of anxiety (70.7 versus 43.2 percent), depression (66.4 versus 38.4 percent), HIV/AIDS (8.5 versus 1.6 percent), and alcohol (57.5 versus 51.0 percent) and viral (30.5 versus 24.2 percent) etiologies, although confidence intervals were overlapping. Similar incidence densities were seen for death, decompensation, and liver transplantation between transgender and cisgender individuals. In addition, similar five-year survival probabilities were seen for transgender and cisgender individuals.

"Our findings suggest that transgender individuals represent a vulnerable population that require specific attention from clinicians and researchers alike," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted July 2024

Read this next

Testosterone Use Not Tied to Gynecological Cancers in Transmasculine Individuals

FRIDAY, May 16, 2025 -- Short-term testosterone use among transmasculine and gender diverse (TMGD) individuals is not associated with an increased risk for gynecological cancers...

General Practitioners Face Barriers to Treating Patients' Sexual Problems

MONDAY, May 12, 2025 -- While treating sexual problems is considered an important health care practice, general practitioners (GPs) report more barriers to caring for...

Gender-Affirming Hormone Therapy in Primary Care Tied to Reduced Depressive Symptoms

MONDAY, March 24, 2025 -- Gender-affirming hormone therapy (GAHT) in primary care is associated with lower rates of moderate-to-severe depressive symptoms in U.S. transgender...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.